Related Experiment Videos
Intensive short course chemotherapy for tuberculous meningitis
R F Jacobs1, P Sunakorn, T Chotpitayasunonah
1Department of Pediatrics, Arkansas Children's Hospital, Little Rock 72202.
The Pediatric Infectious Disease Journal
|March 1, 1992
Summary
A 6-month treatment for tuberculous meningitis in children using pyrazinamide (PZA) is more effective than longer regimens without PZA. This short-course chemotherapy reduces mortality and long-term complications in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Tuberculosis Research
- Clinical Pharmacology
Background:
- Tuberculous meningitis (TBM) poses a significant threat to children, with high mortality and sequelae rates.
- Advanced disease stages at diagnosis correlate with poor outcomes in pediatric TBM.
- Optimal treatment duration and drug combinations for pediatric TBM remain areas of active investigation.
Purpose of the Study:
- To evaluate the efficacy of different treatment durations and drug regimens for pediatric tuberculous meningitis.
- To determine if a shorter chemotherapy course incorporating pyrazinamide (PZA) improves outcomes compared to longer courses without PZA.
- To assess the impact of disease severity at presentation on mortality and sequelae in children with TBM.
Main Methods:
- A nonrandomized, open clinical investigation involving 53 children with Stages I, II, and III tuberculous meningitis.
- Administration of various combinations of standard antitubercular drugs: isoniazid, rifampin, pyrazinamide, streptomycin, and ethambutol.
- Comparison of three treatment durations: 12 months, 9 months, and a 6-month regimen including PZA.
Main Results:
- Severe TBM at presentation was significantly associated with increased early mortality (P < 0.05).
- The 6-month intensive short-course chemotherapy regimen with PZA demonstrated superior efficacy in preventing negative outcomes and sequelae (P < 0.05).
- This shorter regimen was more effective than longer therapies (9 or 12 months) that did not include PZA, irrespective of initial disease stage.
Conclusions:
- A 6-month treatment regimen containing pyrazinamide (PZA) is an effective strategy for treating pediatric tuberculous meningitis.
- Intensive short-course chemotherapy with PZA offers a promising approach to reduce mortality and sequelae in children with TBM.
- Early diagnosis and treatment initiation are crucial, but optimized chemotherapy regimens can significantly improve patient outcomes.